These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 25166271)

  • 21. Long-term functional and morphologic retinal changes after ranibizumab and photodynamic therapy in myopic choroidal neovascularization.
    Parravano M; Ricci F; Oddone F; Missiroli F; De Felici C; Varano M
    Retina; 2014 Oct; 34(10):2053-62. PubMed ID: 24946101
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intravitreal ranibizumab versus bevacizumab for treatment of myopic choroidal neovascularization.
    Iacono P; Parodi MB; Papayannis A; Kontadakis S; Sheth S; Cascavilla ML; Bandello F
    Retina; 2012 Sep; 32(8):1539-46. PubMed ID: 22922846
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term effect of intravitreal injection of anti-VEGF agent for visual acuity and chorioretinal atrophy progression in myopic choroidal neovascularization.
    Oishi A; Yamashiro K; Tsujikawa A; Ooto S; Tamura H; Nakata I; Miyake M; Yoshimura N
    Graefes Arch Clin Exp Ophthalmol; 2013 Jan; 251(1):1-7. PubMed ID: 22527326
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of visual outcome and regression pattern of myopic choroidal neovascularization after intravitreal bevacizumab or after photodynamic therapy.
    Hayashi K; Ohno-Matsui K; Teramukai S; Shimada N; Moriyama M; Hayashi W; Yoshida T; Tokoro T; Mochizuki M
    Am J Ophthalmol; 2009 Sep; 148(3):396-408. PubMed ID: 19427991
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is ellipsoid zone integrity essential for visual recovery in myopic neovascularization after anti-VEGF therapy?
    Milani P; Pellegrini M; Massacesi A; Moschini S; Setaccioli M; Soranna D; Zambon A; Bottoni F; Bergamini F
    Graefes Arch Clin Exp Ophthalmol; 2017 Sep; 255(9):1713-1720. PubMed ID: 28667483
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results.
    Gharbiya M; Allievi F; Mazzeo L; Gabrieli CB
    Am J Ophthalmol; 2009 Jan; 147(1):84-93.e1. PubMed ID: 18774547
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-VEGF therapy in myopic choroidal neovascularization: long-term results.
    Freitas-da-Costa P; Pinheiro-Costa J; Carvalho B; Falcão M; Brandão E; Falcão-Reis F; Carneiro Â
    Ophthalmologica; 2014; 232(1):57-63. PubMed ID: 24852069
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intravitreal bevacizumab (Avastin) as primary treatment for myopic choroidal neovascularization.
    Mandal S; Venkatesh P; Sampangi R; Garg S
    Eur J Ophthalmol; 2007; 17(4):620-6. PubMed ID: 17671940
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intravitreal anti-vascular endothelial growth factor for submacular hemorrhage from choroidal neovascularization.
    Kim JH; Chang YS; Kim JW; Kim CG; Yoo SJ; Cho HJ
    Ophthalmology; 2014 Apr; 121(4):926-35. PubMed ID: 24342019
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopia.
    Sakaguchi H; Ikuno Y; Gomi F; Kamei M; Sawa M; Tsujikawa M; Oshima Y; Kusaka S; Tano Y
    Br J Ophthalmol; 2007 Feb; 91(2):161-5. PubMed ID: 16914470
    [TBL] [Abstract][Full Text] [Related]  

  • 31. One-year outcomes of intravitreal bevacizumab (avastin) therapy for polypoidal choroidal vasculopathy.
    Cheng CK; Peng CH; Chang CK; Hu CC; Chen LJ
    Retina; 2011 May; 31(5):846-56. PubMed ID: 21317837
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intravitreal bevacizumab for treatment of subfoveal idiopathic choroidal neovascularization: results of a 1-year prospective trial.
    Zhang H; Liu ZL; Sun P; Gu F
    Am J Ophthalmol; 2012 Feb; 153(2):300-306.e1. PubMed ID: 21982109
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ranibizumab treatment for choroidal neovascularization secondary to causes other than age-related macular degeneration with good baseline visual acuity.
    Erol MK; Ozdemir O; Coban DT; Ceran BB; Bulut M
    Semin Ophthalmol; 2014 Mar; 29(2):108-13. PubMed ID: 24409939
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical course of choroidal neovascularization secondary to angioid streaks treated with intravitreal bevacizumab.
    Teixeira A; Mattos T; Velletri R; Teixeira R; Freire J; Moares N; Bonomo PP
    Ophthalmic Surg Lasers Imaging; 2010; 41(5):546-9. PubMed ID: 20795575
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Macular functional changes evaluated with MP-1 microperimetry after intravitreal bevacizumab for subfoveal myopic choroidal neovascularization: one-year results.
    Scupola A; Tiberti AC; Sasso P; Savastano MC; Mastrocola A; Marangoni D; Minnella AM; Falsini B; Balestrazzi E
    Retina; 2010 May; 30(5):739-47. PubMed ID: 20038860
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intravitreal bevacizumab for extrafoveal choroidal neovascularization secondary to pathologic myopia.
    Parodi MB; Iacono P; Papayannis A; Kontadakis S; Cascavilla ML; Zucchiatti I; Bandello F
    Retina; 2013 Mar; 33(3):593-7. PubMed ID: 23190919
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Factors associated with enlargement of chorioretinal atrophy after intravitreal bevacizumab for myopic choroidal neovascularization.
    Uemoto R; Nakasato-Sonn H; Kawagoe T; Akira M; Okada E; Mizuki N
    Graefes Arch Clin Exp Ophthalmol; 2012 Jul; 250(7):989-97. PubMed ID: 22270217
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HOW VITREOMACULAR INTERFACE MODIFIES THE EFFICACY OF ANTI-VEGF THERAPY FOR MYOPIC CHOROIDAL NEOVASCULARIZATION.
    Iacono P; Battaglia Parodi M; Iuliano L; Bandello F
    Retina; 2018 Jan; 38(1):84-90. PubMed ID: 28098725
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Myopic choroidal neovascularization.
    Ruiz-Moreno JM; López-Gálvez MI; Donate J; Gomez-Ulla F; García-Arumí J; García-Layana A; Sellés I; Reche J; Montero JA; Pazos B; Zapata MA; Pastor JC
    Ophthalmology; 2011 Dec; 118(12):2521-3. PubMed ID: 22136676
    [No Abstract]   [Full Text] [Related]  

  • 40. Short-term effects of intravitreal bevacizumab for subfoveal choroidal neovascularization in pathologic myopia.
    Hernández-Rojas ML; Quiroz-Mercado H; Dalma-Weiszhausz J; Fromow-Guerra J; Amaya-Espinosa A; Solís-Vivanco A; Reyna-Castelán E; Abraham-Marín M; Martínez-Castellanos MA; Aiello LP
    Retina; 2007; 27(6):707-12. PubMed ID: 17621179
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.